Comprehensive Genomic Profiling and Therapeutic Implications for Patients with Advanced Cancers: The Experience of an Academic Hospital
Next-generation sequencing (NGS) can be used to detect tumor-specific genomic alterations. This retrospective single-center study aims to assess the application of an extensive NGS panel to identify actionable alterations and initiate matched targeted treatment for patients with advanced cancer. We...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/13/9/1619 |
| _version_ | 1797602745365037056 |
|---|---|
| author | Laure-Anne Teuwen Evelyne Roets Pieter D’Hoore Patrick Pauwels Hans Prenen |
| author_facet | Laure-Anne Teuwen Evelyne Roets Pieter D’Hoore Patrick Pauwels Hans Prenen |
| author_sort | Laure-Anne Teuwen |
| collection | DOAJ |
| description | Next-generation sequencing (NGS) can be used to detect tumor-specific genomic alterations. This retrospective single-center study aims to assess the application of an extensive NGS panel to identify actionable alterations and initiate matched targeted treatment for patients with advanced cancer. We analyzed genomic alterations in solid tumor biopsies from 464 patients with advanced cancer with the Foundation Medicine assay (FoundationOne<sup>®</sup>CDx). Therapeutic implications were determined using the Memorial Sloan Kettering Precision Oncology Knowledge Base (OncoKB) classification. The FoundationOne<sup>®</sup>CDx was successfully applied in 464/521 patients (89%). The most common altered genes were TP53 (61%), KRAS (20%), CDKN2A (20%), TERT (16%), and APC (16%). Among the 419 patients with successfully analyzed tumor mutational burden (TMB), 43 patients presented with a high TMB (≥10 mutations/megabase). Out of the 126 patients with an actionable target, 40 patients received matched treatment (32%) of which 17 were within a clinical trial. This study shows that the application of NGS is feasible in an academic center and increases the detection of actionable alterations and identification of patients eligible for targeted treatment or immunotherapy regardless of tumor histology. Strategies such as early referral for NGS, inclusion in clinical (basket) trials, and the development of new targeted drugs are necessary to improve the matched treatment rate. |
| first_indexed | 2024-03-11T04:20:58Z |
| format | Article |
| id | doaj.art-3ba29aae21a2449b854e10def7befe6e |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-11T04:20:58Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-3ba29aae21a2449b854e10def7befe6e2023-11-17T22:46:09ZengMDPI AGDiagnostics2075-44182023-05-01139161910.3390/diagnostics13091619Comprehensive Genomic Profiling and Therapeutic Implications for Patients with Advanced Cancers: The Experience of an Academic HospitalLaure-Anne Teuwen0Evelyne Roets1Pieter D’Hoore2Patrick Pauwels3Hans Prenen4Department of Oncology, Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, BelgiumDepartment of Oncology, Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, BelgiumDepartment of Oncology, Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, BelgiumDepartment of Pathology, Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, BelgiumDepartment of Oncology, Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, BelgiumNext-generation sequencing (NGS) can be used to detect tumor-specific genomic alterations. This retrospective single-center study aims to assess the application of an extensive NGS panel to identify actionable alterations and initiate matched targeted treatment for patients with advanced cancer. We analyzed genomic alterations in solid tumor biopsies from 464 patients with advanced cancer with the Foundation Medicine assay (FoundationOne<sup>®</sup>CDx). Therapeutic implications were determined using the Memorial Sloan Kettering Precision Oncology Knowledge Base (OncoKB) classification. The FoundationOne<sup>®</sup>CDx was successfully applied in 464/521 patients (89%). The most common altered genes were TP53 (61%), KRAS (20%), CDKN2A (20%), TERT (16%), and APC (16%). Among the 419 patients with successfully analyzed tumor mutational burden (TMB), 43 patients presented with a high TMB (≥10 mutations/megabase). Out of the 126 patients with an actionable target, 40 patients received matched treatment (32%) of which 17 were within a clinical trial. This study shows that the application of NGS is feasible in an academic center and increases the detection of actionable alterations and identification of patients eligible for targeted treatment or immunotherapy regardless of tumor histology. Strategies such as early referral for NGS, inclusion in clinical (basket) trials, and the development of new targeted drugs are necessary to improve the matched treatment rate.https://www.mdpi.com/2075-4418/13/9/1619advanced cancergenomic profilingnext-generation sequencingOncoKB classificationtargeted therapy |
| spellingShingle | Laure-Anne Teuwen Evelyne Roets Pieter D’Hoore Patrick Pauwels Hans Prenen Comprehensive Genomic Profiling and Therapeutic Implications for Patients with Advanced Cancers: The Experience of an Academic Hospital Diagnostics advanced cancer genomic profiling next-generation sequencing OncoKB classification targeted therapy |
| title | Comprehensive Genomic Profiling and Therapeutic Implications for Patients with Advanced Cancers: The Experience of an Academic Hospital |
| title_full | Comprehensive Genomic Profiling and Therapeutic Implications for Patients with Advanced Cancers: The Experience of an Academic Hospital |
| title_fullStr | Comprehensive Genomic Profiling and Therapeutic Implications for Patients with Advanced Cancers: The Experience of an Academic Hospital |
| title_full_unstemmed | Comprehensive Genomic Profiling and Therapeutic Implications for Patients with Advanced Cancers: The Experience of an Academic Hospital |
| title_short | Comprehensive Genomic Profiling and Therapeutic Implications for Patients with Advanced Cancers: The Experience of an Academic Hospital |
| title_sort | comprehensive genomic profiling and therapeutic implications for patients with advanced cancers the experience of an academic hospital |
| topic | advanced cancer genomic profiling next-generation sequencing OncoKB classification targeted therapy |
| url | https://www.mdpi.com/2075-4418/13/9/1619 |
| work_keys_str_mv | AT laureanneteuwen comprehensivegenomicprofilingandtherapeuticimplicationsforpatientswithadvancedcancerstheexperienceofanacademichospital AT evelyneroets comprehensivegenomicprofilingandtherapeuticimplicationsforpatientswithadvancedcancerstheexperienceofanacademichospital AT pieterdhoore comprehensivegenomicprofilingandtherapeuticimplicationsforpatientswithadvancedcancerstheexperienceofanacademichospital AT patrickpauwels comprehensivegenomicprofilingandtherapeuticimplicationsforpatientswithadvancedcancerstheexperienceofanacademichospital AT hansprenen comprehensivegenomicprofilingandtherapeuticimplicationsforpatientswithadvancedcancerstheexperienceofanacademichospital |